Literature DB >> 20848280

18F-FDG PET/CT in paediatric lymphoma: comparison with conventional imaging.

Kevin London1, Siobhan Cross, Ella Onikul, Luciano Dalla-Pozza, Robert Howman-Giles.   

Abstract

PURPOSE: In children with Hodgkin's disease and non-Hodgkin's lymphoma, the ability of (18)F-fluoro-2-deoxy-D-glucose PET/CT and conventional imaging (CI) to detect malignant lesions and predict poor lesion response to therapy was assessed and compared.
METHODS: A retrospective review of findings reported on PET/CT and CI was performed using a lesion-based analysis of 16 lymph node and 8 extra-nodal regions. Lesions were defined by histopathological findings or follow-up > 6 months.
RESULTS: The study included 209 PET/CT scans with a valid CI comparator. A total of 5,014 regions (3,342 lymph node, 1,672 extra-nodal) were analysed. PET/CT performed significantly better than CI in the detection of malignant lesions with sensitivity and specificity of 95.9 and 99.7% compared to 70.1 and 99.0%, respectively. For predicting poor lesion response to therapy, PET/CT had fewer false-positive lesions than CI. The specificity for predicting poor lesion response to treatment for PET/CT was 99.2% compared to 96.9% for CI. PET/CT was the correct modality in 86% of lesions with discordant findings.
CONCLUSION: PET/CT is more accurate than CI in detecting malignant lesions in childhood lymphoma and in predicting poor lesion response to treatment. In lesions with discordant findings, PET/CT results are more likely to be correct.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20848280     DOI: 10.1007/s00259-010-1619-6

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  23 in total

1.  F-18 FDG-PET imaging and correlation with CT in staging and follow-up of pediatric lymphomas.

Authors:  Miguel Hernandez-Pampaloni; Amol Takalkar; Jian Q Yu; Hongming Zhuang; Abass Alavi
Journal:  Pediatr Radiol       Date:  2006-04-19

2.  Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease.

Authors:  M R Weihrauch; D Re; S Bischoff; M Dietlein; K Scheidhauer; B Krug; F Textoris; S Ansén; J Franklin; H Bohlen; J Wolf; H Schicha; V Diehl; H Tesch
Journal:  Ann Hematol       Date:  2001-12-12       Impact factor: 3.673

3.  Staging in childhood lymphoma: differences between FDG-PET and CT.

Authors:  S Hermann; D Wormanns; M Pixberg; A Hunold; W Heindel; H Jürgens; O Schober; C Franzius
Journal:  Nuklearmedizin       Date:  2005-02       Impact factor: 1.379

4.  Comparison of 18F-FDG-PET and standard procedures for the pretreatment staging of children and adolescents with Hodgkin's disease.

Authors:  Edita Kabickova; David Sumerauer; Eliska Cumlivska; Eva Drahokoupilova; Michaela Nekolna; Marketa Chanova; Marie Hladikova; Roman Kodet; Otakar Belohlavek
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-03-25       Impact factor: 9.236

Review 5.  [18F]-FDG positron imaging in clinical management of lymphoma patients.

Authors:  J N Talbot; C Haioun; J D Rain; M Meignan; M Wioland; J L Misset; D Grahek; K Kerrou; F Montravers
Journal:  Crit Rev Oncol Hematol       Date:  2001-06       Impact factor: 6.312

6.  18F-FDG PET in children with lymphomas.

Authors:  Gisele Depas; Caroline De Barsy; Guy Jerusalem; Claire Hoyoux; Marie-Françoise Dresse; Marie-France Fassotte; Nancy Paquet; Jacqueline Foidart; Pierre Rigo; Roland Hustinx
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-07-24       Impact factor: 9.236

Review 7.  18F-FDG PET for posttherapy assessment of Hodgkin's disease and aggressive Non-Hodgkin's lymphoma: a systematic review.

Authors:  Teruhiko Terasawa; Takashi Nihashi; Tomomitsu Hotta; Hirokazu Nagai
Journal:  J Nucl Med       Date:  2007-12-12       Impact factor: 10.057

8.  Role of PET/CT in malignant pediatric lymphoma.

Authors:  Raef Riad; Walid Omar; Magdy Kotb; Magdy Hafez; Iman Sidhom; Manal Zamzam; Iman Zaky; Hussein Abdel-Dayem
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-09-15       Impact factor: 9.236

9.  (18)F-FDG PET in Pediatric Lymphomas: A Comparison with Conventional Imaging.

Authors:  Egesta Lopci; Roberta Burnelli; Valentina Ambrosini; Cristina Nanni; Paolo Castellucci; Lorenzo Biassoni; Domenico Rubello; Stefano Fanti
Journal:  Cancer Biother Radiopharm       Date:  2008-12       Impact factor: 3.099

10.  [(18)F]FDG in childhood lymphoma: clinical utility and impact on management.

Authors:  F Montravers; D McNamara; J Landman-Parker; D Grahek; K Kerrou; N Younsi; M Wioland; G Leverger; J N Talbot
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-06-25       Impact factor: 9.236

View more
  14 in total

Review 1.  Clinical pediatric positron emission tomography/magnetic resonance program: a guide to successful implementation.

Authors:  Sandra Saade-Lemus; Elad Nevo; Iman Soliman; Hansel J Otero; Ralph W Magee; Elizabeth T Drum; Lisa J States
Journal:  Pediatr Radiol       Date:  2020-02-19

Review 2.  FDG PET/CT in children and adolescents with lymphoma.

Authors:  Regine Kluge; Lars Kurch; Françoise Montravers; Christine Mauz-Körholz
Journal:  Pediatr Radiol       Date:  2013-03-24

Review 3.  2-deoxy-2-((18)F)fluoro-D-glucose positron emission tomography/computed tomography imaging in paediatric oncology.

Authors:  John Freebody; Eva A Wegner; Monica A Rossleigh
Journal:  World J Radiol       Date:  2014-10-28

4.  Imaging children suffering from lymphoma: an evaluation of different 18F-FDG PET/MRI protocols compared to whole-body DW-MRI.

Authors:  Julian Kirchner; Cornelius Deuschl; Bernd Schweiger; Ken Herrmann; Michael Forsting; Christian Buchbender; Gerald Antoch; Lale Umutlu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-05-22       Impact factor: 9.236

5.  Value of FDG-PET/CT examinations in different cancers of children, focusing on lymphomas.

Authors:  Edit Bárdi; Mónika Csóka; Ildikó Garai; István Szegedi; Judit Müller; Tamás Györke; Kornélia Kajáry; Karolina Nemes; Csongor Kiss; Gábor Kovács
Journal:  Pathol Oncol Res       Date:  2013-08-17       Impact factor: 3.201

6.  How to Provide Gadolinium-Free PET/MR Cancer Staging of Children and Young Adults in Less than 1 h: the Stanford Approach.

Authors:  Anne M Muehe; Ashok J Theruvath; Lillian Lai; Maryam Aghighi; Andrew Quon; Samantha J Holdsworth; Jia Wang; Sandra Luna-Fineman; Neyssa Marina; Ranjana Advani; Jarrett Rosenberg; Heike E Daldrup-Link
Journal:  Mol Imaging Biol       Date:  2018-04       Impact factor: 3.488

7.  Diagnostic value of combined ¹⁸F-FDG PET/MRI for staging and restaging in paediatric oncology.

Authors:  Thomas Pfluger; Henriette I Melzer; Wolfgang P Mueller; Eva Coppenrath; Peter Bartenstein; Michael H Albert; Irene Schmid
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-08-28       Impact factor: 9.236

8.  Evaluation of diagnostic performance of whole-body simultaneous PET/MRI in pediatric lymphoma.

Authors:  Maria Rosana Ponisio; Jonathan McConathy; Richard Laforest; Geetika Khanna
Journal:  Pediatr Radiol       Date:  2016-03-22

9.  Prognostic Value and Clinical Impact of (18)FDG-PET in the Management of Children with Burkitt Lymphoma after Induction Chemotherapy.

Authors:  Clément Bailly; Thomas Eugène; Marie-Laure Couec; Marion Strullu; Eric Frampas; Loïc Campion; Françoise Kraeber-Bodéré; Caroline Bodet-Milin
Journal:  Front Med (Lausanne)       Date:  2014-12-16

10.  The usefulness of (18)F-FDG PET/CT for assessing methotrexate-associated lymphoproliferative disorder (MTX-LPD).

Authors:  Shiro Watanabe; Osamu Manabe; Kenji Hirata; Noriko Oyama-Manabe; Naoya Hattori; Yasuka Kikuchi; Kentaro Kobayashi; Takuya Toyonaga; Nagara Tamaki
Journal:  BMC Cancer       Date:  2016-08-15       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.